Shares of Vascular Solutions Inc. (NASDAQ:VASC) have been given an average rating of “Buy” by the six ratings firms that are presently covering the firm. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $51.33.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Vascular Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th. Needham & Company LLC assumed coverage on Vascular Solutions in a research note on Thursday, October 6th. They issued a “buy” rating and a $58.00 target price for the company. Canaccord Genuity reissued a “buy” rating on shares of Vascular Solutions in a research note on Wednesday, August 10th. TheStreet raised Vascular Solutions from a “hold” rating to a “buy” rating in a research note on Monday, July 25th. Finally, Sidoti cut Vascular Solutions from a “buy” rating to a “neutral” rating and set a $47.00 target price for the company. in a research note on Tuesday, July 12th.
In related news, CEO Howard Root sold 40,000 shares of Vascular Solutions stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $45.11, for a total transaction of $1,804,400.00. Following the completion of the sale, the chief executive officer now directly owns 347,840 shares of the company’s stock, valued at $15,691,062.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP William Rutstein sold 10,011 shares of Vascular Solutions stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $46.26, for a total value of $463,108.86. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.
Several large investors have recently made changes to their positions in VASC. Ruffer LLP boosted its stake in shares of Vascular Solutions by 22.2% in the first quarter. Ruffer LLP now owns 55,000 shares of the medical device company’s stock worth $1,790,000 after buying an additional 10,000 shares during the period. Menta Capital LLC bought a new stake in shares of Vascular Solutions during the first quarter worth approximately $320,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Vascular Solutions during the first quarter worth approximately $2,590,000. Prudential Financial Inc. boosted its stake in shares of Vascular Solutions by 3.7% in the first quarter. Prudential Financial Inc. now owns 42,347 shares of the medical device company’s stock worth $1,378,000 after buying an additional 1,500 shares during the period. Finally, Eagle Asset Management Inc. boosted its stake in shares of Vascular Solutions by 5.7% in the second quarter. Eagle Asset Management Inc. now owns 246,900 shares of the medical device company’s stock worth $10,285,000 after buying an additional 13,346 shares during the period. 82.08% of the stock is owned by institutional investors and hedge funds.
Shares of Vascular Solutions (NASDAQ:VASC) opened at 48.29 on Thursday. The stock has a market capitalization of $844.64 million, a P/E ratio of 89.43 and a beta of 0.54. The company has a 50-day moving average price of $48.52 and a 200 day moving average price of $41.87. Vascular Solutions has a 52 week low of $24.34 and a 52 week high of $50.72.
Vascular Solutions (NASDAQ:VASC) last released its quarterly earnings results on Monday, July 25th. The medical device company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.03. Vascular Solutions had a return on equity of 16.32% and a net margin of 6.22%. The firm earned $41.20 million during the quarter, compared to analysts’ expectations of $41.40 million. During the same period last year, the firm posted $0.29 EPS. The business’s revenue was up 9.7% on a year-over-year basis. Analysts forecast that Vascular Solutions will post $1.24 earnings per share for the current fiscal year.
Vascular Solutions Company Profile
Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.
Receive News & Ratings for Vascular Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.